Poor
Mostly Aligned
Patient Risk:
Low
Summary
Only one claim is clearly evaluable for label alignment (indication for adult growth hormone deficiency); several other claims are about pricing/access/administrative steps and cannot be supported or contradicted by the provided prescribing information excerpts. The remaining clinical-testing pathway claims are not supported or contradicted because the provided label excerpts do not describe alternative testing approaches beyond effects of CYP3A4 inducers/medications and situations warranting repeat testing.
Category Scores
Accurate Statements
Macrilen (macimorelin) is a prescription drug used to diagnose growth hormone deficiency.
Section 1: MACRILEN is indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Unsupported Statements
Publicly available pricing information for Macrilen can vary by pharmacy, insurance status, and whether the patient uses a manufacturer program.
No pricing/coverage/program information is provided in the supplied prescribing information excerpts.
The most reliable way to get a current out-of-pocket estimate for Macrilen is to use a pharmacy quote or a prescription discount card at checkout.
No out-of-pocket estimation or retail/discount guidance is provided in the supplied prescribing information excerpts.
List price and negotiated prices for Macrilen change.
No pricing statements are provided in the supplied prescribing information excerpts.
Your cost for Macrilen typically depends on insurance coverage (commercial insurance vs. Medicare/Medicaid).
No cost/coverage dependence is provided in the supplied prescribing information excerpts.
Your cost for Macrilen typically depends on whether your plan requires prior authorization.
No prior authorization/cost linkage is provided in the supplied prescribing information excerpts.
Your cost for Macrilen typically depends on your pharmacy’s contracted price.
No pharmacy contracted price statements are provided in the supplied prescribing information excerpts.
Your cost for Macrilen typically depends on your deductible and copay/coinsurance.
No deductible/copay/coinsurance statements are provided in the supplied prescribing information excerpts.
Your cost for Macrilen typically depends on whether you use a copay assistance or patient assistance program when eligible.
No assistance-program/cost guidance is provided in the supplied prescribing information excerpts.
If you use insurance, you can check your insurance drug formulary for macimorelin/Macrilen tier and copay/coinsurance.
No formulary/tier/copay/coinsurance guidance is provided in the supplied prescribing information excerpts.
If you have insurance, you can ask whether prior authorization is needed for coverage of Macrilen.
No payer/coverage/prior authorization guidance is provided in the supplied prescribing information excerpts.
For growth hormone deficiency diagnosis, doctors may use other established testing approaches depending on the patient and setting.
The provided label excerpts do not describe other diagnostic testing approaches; they focus on MACRILEN diagnostic interpretation/cutoff and specific issues (e.g., false positives/false negatives, repeat testing in recent onset hypothalamic disease).
For growth hormone deficiency diagnosis, different stimulation tests or imaging pathways may be used as alternative testing approaches.
The provided label excerpts do not describe alternative stimulation tests or imaging pathways; they only address MACRILEN test interpretation and medication-related factors that affect test results.
Contradictions
Low
AI Statement
Macrilen (macimorelin) is a prescription drug used to diagnose growth hormone deficiency.
Label Reference
Section 1: MACRILEN is indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Important Omissions
The indication in the label is specifically for adult growth hormone deficiency (AGHD); the claim does not specify 'adult' and could be read as non-age-specific growth hormone deficiency diagnosis.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most statements relate to pricing/access and are not addressed in the label excerpts. The only label-relevant medical statement is partially imprecise by omitting 'adult' from the labeled indication; no contraindication/dosing/warning misuse is asserted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Many claims are outside the scope of the provided prescribing information (pricing/insurance navigation) and cannot be validated against the label; two diagnostic-alternative testing claims are not supported by the provided excerpts.
Suggested Improvement
Restrict medical statements to what the label excerpt supports (e.g., specify 'adult growth hormone deficiency' per Section 1; avoid asserting alternative testing modalities not described in the provided label excerpts). For non-medical topics (pricing/insurance), omit or clearly separate from label-based claims.